Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
Moderna reported a fourth-quarter revenue of $1.0 billion and a GAAP net loss of $1.1 billion, with a full-year revenue of $3.2 billion and a net loss of $3.6 billion. The company expects 2025 revenue between $1.5 to $2.5 billion and has submitted three investigational mRNA products for regulatory approval.
February 14, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Moderna reported significant losses for Q4 and FY 2024, with expectations of lower revenue in 2025. However, the submission of three mRNA products for regulatory approval, including a next-gen COVID vaccine, could positively impact future revenues.
The reported financial losses for both the quarter and the year are likely to negatively impact Moderna's stock in the short term. However, the submission of new mRNA products for approval, including a next-gen COVID vaccine, could provide a future revenue boost, partially offsetting the negative sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100